Cynata Therapeutics Limited
CYYNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | -$0 | $2 | -$0 | $3 |
| % Growth | -104.3% | 956.3% | -109% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $2 | -$0 | $1 |
| % Margin | 100% | 100% | 100% | 44.5% |
| R&D Expenses | $8 | $0 | $4 | $5 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $5 | $2 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$6 |
| Operating Expenses | $10 | $5 | $5 | $6 |
| Operating Income | -$10 | -$3 | -$2 | -$3 |
| % Margin | 11,755.8% | -131.1% | 748.1% | -134.2% |
| Other Income/Exp. Net | $4 | -$1 | -$3 | -$3 |
| Pre-Tax Income | -$6 | -$4 | -$5 | -$7 |
| Tax Expense | $0 | $0 | $0 | -$2 |
| Net Income | -$6 | -$4 | -$5 | -$5 |
| % Margin | 6,755.1% | -185.3% | 2,261.8% | -178.4% |
| EPS | -0.025 | -0.02 | -0.029 | -0.025 |
| % Growth | -28.3% | 31.7% | -14.6% | – |
| EPS Diluted | -0.025 | -0.02 | -0.029 | -0.025 |
| Weighted Avg Shares Out | 226 | 184 | 180 | 180 |
| Weighted Avg Shares Out Dil | 226 | 184 | 180 | 180 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$4 | -$6 | -$7 |
| % Margin | 6,842.2% | -178.3% | 2,411.9% | -272.9% |